Dalbavancin

Kathryn Dzintars, Pharm.D., BCPS, Paul Pham, Pharm.D.
Dalbavancin is a topic covered in the Johns Hopkins ABX Guide.

To view the entire topic, please or .

Official website of the Johns Hopkins Antibiotic (ABX), HIV, Diabetes, and Psychiatry Guides, powered by Unbound Medicine. Johns Hopkins Guide App for iOS, iPhone, iPad, and Android included. Explore these free sample topics:

-- The first section of this topic is shown below --

INDICATIONS

FDA

  • Treatment of acute bacterial skin and skin structure infections (ABSSSI) caused by susceptible Gram-positive organism.
    • S. aureus(including MRSA), S. pyogenes, S. agalactiae, S. dysgalactiae, S. anginosus group, E. faecalis (vancomycin-susceptible)

NON-FDA APPROVED USES

No data on the use of dalbavancin for other infections, e.g., S. aureus infections (pneumonia, bacteremia, endocarditis)

-- To view the remaining sections of this topic, please or --

INDICATIONS

FDA

  • Treatment of acute bacterial skin and skin structure infections (ABSSSI) caused by susceptible Gram-positive organism.
    • S. aureus(including MRSA), S. pyogenes, S. agalactiae, S. dysgalactiae, S. anginosus group, E. faecalis (vancomycin-susceptible)

NON-FDA APPROVED USES

No data on the use of dalbavancin for other infections, e.g., S. aureus infections (pneumonia, bacteremia, endocarditis)

There's more to see -- the rest of this topic is available only to subscribers.

Last updated: January 30, 2017